| Date | Title | Description |
| 07.06.2023 | ChromaCode Receives Strategic Investment From Shimadzu Future Innovation Fund | ChromaCode, a Carlsbad, CA-based genomics multiplexing platform company developing accessible and affordable solutions for laboratories, patients and physicians, received a strategic investment from corporate venture capital fund Shimadzu F... |
| 12.08.2021 | ChromaCode Adds Industry Leaders, Pat Balthrop And Kevin O’Boyle, To Board Of Directors | ChromaCode, Inc., a company that combines data science and proprietary reagents to improve clinical molecular analysis, announced that Patrick Balthrop, Sr. and Kevin O’Boyle have joined the company’s Board of Directors.
Recommended AI News... |
| 26.01.2021 | Founders of molecular diagnostics company ChromaCode share ambitions for their business | ChromaCode Co-Founders Alex Dickinson, Executive Chairman, Aditya Rajagopal, CTO, and CEO Greg Gosch talk about the formation of their molecular testing startup.
Why did you start this company?
Alex: I had started several companies with Pro... |
| 15.01.2021 | StartUPDATES: New developments for healthcare startups | ChromaCode has been named a finalist in the XPRIZE Rapid Covid Testing Competition, which aims to increase testing capabilities & accelerate the development of high-quality testing that is low cost, easy to use & quick reporting.
Tu... |
| 13.11.2020 | StartUPDATES: New developments from healthcare startups | ChromaCode’s Board Member Carol Gallagher was recently named this year’s honoree for Companies in Transition from the Corporate Directors Forum for her work to assess & balance financing and transaction alternatives for the company.
Neu... |
| 26.10.2020 | StartUPDATES: New developments from healthcare startups | “To break the cost curve for both employers and employees, we went all-in on building a health plan that provides the tools needed to see cost and quality comparisons, as well as treatment path options across conditions. And we removed unne... |
| 09.10.2020 | StartUPDATES: New developments for healthcare startups | ChromaCode’s HDPCR™ SARS-CoV-2 assay has moved on to the Semi-Finals Round of the XPRIZE Rapid Covid Testing Competition, aiming to increase Covid-19 testing capabilities 100-times past our current standard.
R3 Vascular, a medical device co... |
| 09.06.2020 | ChromaCode Receives $38M In Funding | ChromaCode, a Carlsbad-based molecular diagnostics company announced it closed a $38 million Series C funding round to pursue low-cost testing platform for coronavirus and other illnesses...
Take 1 minute to subscribe and you'll get this st... |
| 09.06.2020 | ChromaCode has raised an additional $10M, raising their Series C round to $38M | - |
| 22.05.2020 | Carlsbad’s ChromaCode raises $38 million to pursue low-cost testing platform for coronavirus | ChromaCode, a Carlsbad startup that taps data science and signal processing to enhance molecular medical tests, has raised $38 million in a third round of venture capital funding to support its low-cost assay for COVID-19.
The 45-employee f... |
| 19.05.2020 | ChromaCode Announces $10M Series C Extension |
CARLSBAD, CA, ChromaCode, a company redefining molecular testing through data science, today announced a $10 million Series C extension with an investment from Adjuvant Capital.
>> Click here for more funding data on ChromaCode
&g... |
| 19.05.2020 | ChromaCode Raises $10M in Series C Financing | ChromaCode, Inc., a Carlsbad, Calif.-based molecular testing company, raised $10m in Series C extension with an investment from Adjuvant Capital.
The investment brings the company’s total Series C funding to $38m. Managing Partner Jenny Yip... |
| 19.05.2020 |
ChromaCode Snags $10M In Series C
| Carlsbad-based ChromaCode, which is developing molecular testing equipment, announced today that it has raised $10M in a Series C extension round. The funding came from Adjuvant Capital. As part of the funding, ChromaCode said that it will ... |
| 18.12.2019 | ChromaCode Scores $28M in Series C |
CARLSBAD, CA, Molecular diagnostics company, announced it has closed a $28 million Series C financing round, led by Northpond Ventures.
>> Click here for more funding data on ChromaCode
>> To export ChromaCode funding data t... |
| 17.12.2019 |
ChromaCode Collects $28M
| Carlsbad-based molecular diagnostics developer ChromaCode has raised $28M in a Series C funding, the company announced this morning, in a funding led by Northpond Ventures. The new funding round also included Windham Ventures, Moore Venture... |
| 17.12.2019 | ChromaCode Raises $28M in Series C Funding | ChromaCode, Inc., a Carlsbad, Calif.-based molecular diagnostics company, secured $28m in Series C financing.
The round was led by Northpond Ventures with participation from new investors Windham Ventures, Moore Venture Partners and the Cal... |
| 17.12.2019 | ChromaCode has raised a $28M Series C financing to accelerate development of their methods of using digital signal processing algorithms for clinical diagnostics | - |
| 27.04.2017 | ChromaCode Raises $12 Million in Series B for Commercial Launch and Appoints Alex Dickinson as Executive Chair | |
| 27.04.2017 | Term Sheet — Thursday, April 27 | PETER PAN NEVER HAD TO GROW UP
The following article is from Fortune’s latest issue.
Paid Content What you need to know about growing cyberattacks From ExtraHop
They’re so exuberant, one VC even declared on CNBC that this year “could be one... |
| 27.04.2017 | ChromaCode Snags $12M Series B Round |
CARLSBAD, CA, ChromaCode, a molecular diagnostics company, today announced it has raised $12 million in Series B funding.
>> Click here for more funding data on ChromaCode
>> To export ChromaCode funding data to PDF and Exce... |
| 27.04.2017 | NEA Leads $12M Series B for ChromaCode | ChromaCode, Inc., a molecular diagnostics company, today announced it has raised $12 million in Series B funding. This latest round is led by New Enterprise Associates (NEA) with participation from existing investors Domain Associates, who ... |
| 27.04.2017 | ChromaCode Raises $12 Million in Series B Round | ChromaCode Inc., a molecular information startup in San Diego, has raised $12 million in a Series B funding and appointed a former Illumina executive as the company’s executive chairman.
The new round was led by New Enterprise Associates, w... |
| 27.04.2017 | Domain Associates Joins $12M Series B for ChromaCode | ChromaCode, Inc., a molecular diagnostics company, today announced it has raised $12 million in Series B funding. This latest round is led by New Enterprise Associates (NEA) with participation from existing investors Domain Associates, who ... |
| 27.04.2017 |
ChromaCode Finds $12M For Molecular Diagnostics Efforts
| Carlsbad-based ChromaCode, a developer of molecular diagnostics technology, announced on Thursday that it has raised $12M in a Series B funding round. The funding was led by New Enterprise Associates (NEA), and also included Domain Associat... |
| 27.04.2017 | ChromaCode Raises $12M in Series B Funding | ChromaCode, Inc., a Carlsbad, Calif.-based molecular diagnostics company, raised $12m in Series B funding.
The round was led by New Enterprise Associates (NEA) with participation from existing investors Domain Associates and Okapi Ventures.... |
| - | StartUPDATES: New developments for healthcare startups | ChromaCode has been named a finalist in the XPRIZE Rapid Covid Testing Competition, which aims to increase testing capabilities & accelerate the development of high-quality testing that is low cost, easy to use & quick reporting.
Tu... |
| - | Founders of molecular diagnostics company ChromaCode share ambitions for their business | ChromaCode Co-Founders Alex Dickinson, Executive Chairman, Aditya Rajagopal, CTO, and CEO Greg Gosch talk about the formation of their molecular testing startup.
Why did you start this company?
Alex: I had started several companies with Pro... |
| - | StartUPDATES: New developments from healthcare startups | Bind announced a $105 million Series B funding round, as investors show continued confidence in the Bind approach to health insurance innovation and market interest.
Bind believes people deserve to see treatment options and compare costs in... |
| - | StartUPDATES: New developments from healthcare startups | ChromaCode’s Board Member Carol Gallagher was recently named this year’s honoree for Companies in Transition from the Corporate Directors Forum for her work to assess & balance financing and transaction alternatives for the company.
Neu... |
| - | StartUPDATES: New developments for healthcare startups | ChromaCode’s HDPCR™ SARS-CoV-2 assay has moved on to the Semi-Finals Round of the XPRIZE Rapid Covid Testing Competition, aiming to increase Covid-19 testing capabilities 100-times past our current standard.
R3 Vascular, a medical device co... |
